These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24671840)

  • 1. [Oral hypoglycemic drugs in chronic kidney disease: which limitations in the clinical setting].
    Granata A; Insalaco M; Di Nicolò P; Scarfia VR; Russo L; D'anna G; Lentini P; Fiorini F; Fatuzzo P
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease.
    Reilly JB; Berns JS
    Semin Dial; 2010; 23(2):163-8. PubMed ID: 20210915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease.
    Snyder RW; Berns JS
    Semin Dial; 2004; 17(5):365-70. PubMed ID: 15461745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of oral hypoglycemic agents in patients with chronic kidney failure].
    Libardi F; Sirolli V; Cappelli P; Bonomini M
    G Ital Nefrol; 2009; 26(6):679-85. PubMed ID: 19918750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
    Abe M; Okada K
    Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents.
    Di Lullo L; Mangano M; Ronco C; Barbera V; De Pascalis A; Bellasi A; Russo D; Di Iorio B; Cozzolino M
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S295-S305. PubMed ID: 28292575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].
    Katsuno T; Miyagawa J
    Nihon Rinsho; 2012 May; 70 Suppl 3():693-8. PubMed ID: 22768600
    [No Abstract]   [Full Text] [Related]  

  • 13. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
    Jojima T; Aso Y
    Nihon Rinsho; 2013 Nov; 71(11):1987-92. PubMed ID: 24397171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
    Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
    Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antidiabetic agents and renal insufficiency].
    Robles NR; Blanco J
    Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.